

WHAT IS CLAIMED IS:

1 1. A system for averting undesirable pharmacokinetic drug interaction
2 between a drug and concomitant drug(s), which comprises controlling the *in vivo* release time
3 and/or release site of the drug and/or the concomitant drug(s).

1 2. A system for averting undesirable drug interaction between a drug and
2 concomitant drug(s), both of which use the same route in terms of *in vivo* drug absorption,
3 distribution, metabolism or excretion in humans, which comprises controlling the *in vivo*
4 release time and/or release site of the drug and/or the concomitant drug(s).

1 3. A system for averting undesirable drug interaction between a drug and
2 concomitant drug(s), both of which are metabolized by the same molecular species of drug-
3 metabolizing enzyme in humans, or between a drug and concomitant drug(s) that is
4 metabolized by the molecular species of drug-metabolizing enzymes that is inhibited by the
5 said drug, which comprises timed-release control of the said drug or control of the site of
6 release of the said drug to the digestive tract.

1 4. A system for averting undesirable drug interaction between a drug and
2 concomitant drug(s), both of which metabolized by the drug metabolizing enzyme CYP3A4,
3 or between a drug that inhibits CYP3A4 and concomitant drug(s) that is metabolized by
4 CYP3A4, which comprises timed-release control of the said drug or controlling release
5 specifically in the lower digestive tract of the said drug.

1 5. A drug preparation for averting undesirable pharmacokinetic drug
2 interaction between a drug and concomitant drug(s), which comprises controlling the *in vivo*
3 release time and/or release site of the said drug.

1 6. A drug preparation for averting undesirable drug interaction between a
2 drug and concomitant drug(s), both of which use the same route in terms of *in vivo* drug
3 absorption, distribution, metabolism or excretion in humans, which comprises controlling the
4 *in vivo* release time and/or release site of the said drug.

1 7. A drug preparation for averting undesirable drug interaction on the *in*
2 *vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism of the said
3 drug in humans, which comprises timed-release control of the concomitant drug or control of
4 the site of release of the concomitant drug to the digestive tract.

1 8. A drug preparation for averting undesirable effects on the blood
2 concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism of the
3 said drug by CYP3A4 in humans, which comprises timed release control of the said drug or
4 controlling release specifically in the lower digestive tract of the concomitant drug.

1 9. The drug preparation according to Claim 8; whereby the said drug and
2 the concomitant drug are a combination selected from anfenbutyl, fentanyl, sufentanil,
3 cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin, clarithromycin,
4 troleandomycin, azithromycin, itraconazole, ketoconazole, dapson, midazolam, triazolam,
5 alprazolam, diazepam, zolpidem, felodipine, nifedipine, nitrendipine, amlodipine, isradipine,
6 nicardipine, nimodipine, nisoldipine, nildipine, bepridil, diltiazem, verapamil, astemizole,
7 terfenadine, loratidine, cyclosporine, tacrolimus, rapamycin, amiodarone, disopyramide,
8 lidocaine, propafenone, quinidine, imipramine, amitriptyline, clomipramine, nafazodone,
9 sertraline, trazodone, haloperidol, pimozone, carbamazepine, ethosuximide, trimethadione,
10 simvastatin, lovastatin, fluvastatin, atorvastatin, etoposide, ifosfamide, paclitaxel, tamoxifen,
11 taxol, vinblastine, vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
12 methylprednisolone, dexamethasone, progesterone, warfarin, finasteride, flutamide, ondansetron,
13 zolsetron, cisapride, cortisol, zonisamide, desmethyldiazepam, and conivaptan.

1 10. A method for averting undesirable pharmacokinetic drug interaction
2 between a drug and concomitant drug(s), comprising administering to patients a drug
3 preparation with which the *in vivo* release time and/or release site of the said drug is
4 controlled.

1 11. A method for averting undesirable drug-interaction between a drug and
2 concomitant drug, both of which use the same route in terms of *in vivo* drug absorption,
3 distribution, metabolism or excretion in humans, comprising administering to patients a drug
4 preparation with which the *in vivo* release time and/or release site of the said drug is
5 controllable.

1 12. A method for averting undesirable drug-interaction on the *in vivo*
2 kinetics of a drug by concomitant drug that inhibits the *in vivo* metabolism of the said drug by
3 drug-metabolizing enzymes in humans, comprising administering to patients a drug
4 preparation with which timed-release of the concomitant drug or release site of the
5 concomitant drug to the digestive tract is controllable.

1 13. A method for averting undesirable effects on the blood concentration
2 of a drug by concomitant drug that inhibits the *in vivo* metabolism of the said drug by
3 CYP3A4, comprising administering to patients a drug preparation with which timed-release
4 of the concomitant drug or release of the concomitant drug specifically to the lower digestive
5 tract is controllable.

1 14. The method according to Claim 13, whereby the said drug and the
2 concomitant drug are a combination selected from anfentanyl, fentanyl, sulfentanyl, cocaine,
3 dihydrocodeine, oxycodone, tramadol, erythromycin, clarithromycin, troleandomycin,
4 azithromycin, itraconazole, ketoconazole, dapsone, midazolam, triazolam, alprazolam,
5 diazepam, zolpidem, felodipine, nifedipine, nitrendipine, amlodipine, isradipine, nicardipine,
6 nimodipine, nisoldipine, nildipine, bepridil, diltiazem, verapamil, astemizole, terfenadine,
7 loratidine, cyclosporine, tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine,
8 propafenone, quinidine, imipramine, amitriptyline, clomipramine, nafazodone, sertraline,
9 trazodone, haloperidol, pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin,
10 lovastatin, fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol,
11 vinblastine, vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
12 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide, ondasteron,
13 zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and conivaptan.

1 15. A system for averting undesirable pharmacokinetic interaction between
2 a drug and food(s), which comprises controlling the *in vivo* release time and/or release site of
3 the drug.